Financing funds development of respiratory therapy

Gilde Healthcare Partners has announced an investment in Prosonix, a developer of respiratory therapies based on its proprietary particle-engineering technology.

Alongside Gilde Healthcare Partners, new investor Ventech participated in an £11.4m financing round. Current backers Entrepreneurs Fund, Quest for Growth and Solon Ventures also participated.

The proceeds of the financing will be used to progress the Prosonix’s emerging proprietary product pipeline of mono- and multi-component combination therapies, and to fund Phase 2 Clinical trials as required.

Oxford-based Prosonix’s patented particle-engineering technology is said to provide an opportunity to develop novel and generic mono and combination respiratory medicines in a range of metered dose and dry-powder inhalers.

As part of the financing, Edwin de Graaf from Gilde Healthcare Partners and Karl Nägler from Ventech will join the Prosonix board of directors.